Real Estate & Construction » Real Estate | Panacea Global Inc.

Panacea Global Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2009
2010
2011
2012
2013
Sales/Revenue
3.30
-
-
-
-
Cost of Goods Sold (COGS) incl. D&A
-
-
220.00
191.20
-
Gross Income
3.30
-
220.00
191.20
-
SG&A Expense
798.70
66.40
1,763.60
774.50
1,441.10
EBIT
795.40
66.40
1,983.70
965.60
1,460.00
Unusual Expense
-
39.30
-
-
-
Non Operating Income/Expense
-
-
84.20
-
-
Pretax Income
795.40
105.70
2,067.90
968.80
1,460.90
Income Tax
-
-
-
46.60
71.10
Consolidated Net Income
795.40
105.70
2,067.90
1,015.40
1,532.00
Net Income
795.40
105.70
2,067.90
1,015.40
1,532.00
Net Income After Extraordinaries
795.40
105.70
2,067.90
1,015.40
1,532.00
Net Income Available to Common
795.40
105.70
2,067.90
1,015.40
1,532.00
EPS (Basic)
0.01
0.00
0.02
0.01
0.02
Basic Shares Outstanding
85,372.60
64,960.30
93,411.30
95,285.70
99,967.90
EPS (Diluted)
0.01
0.00
0.02
0.01
0.02
Diluted Shares Outstanding
85,372.60
64,960.30
93,411.30
95,285.70
99,967.90
EBITDA
795.40
66.40
1,980.30
950.50
1,441.10
Equity in Affiliates (Pretax)
-
-
-
3.20
0.90

About Panacea Global

View Profile
Address
330 Highway 7 East
Richmond Hill Ontario L4B 3P8
Canada
Employees -
Website -
Updated 09/14/2018
Panacea Global, Inc. is a biotechnology company focused on the discovering, developing and commercializing of diagnostic products for the management of cancer. The company provides blood, serum and tissue tests to diagnose and monitor cancer through a licensing agreement with Panacea Pharmaceuticals. Its current product line allows for accurate detection of the most common forms of cancer, which includes diagnostic tests for lung, breast, prostate and colon cancers.